Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Wang, E. S.; Stone, R. M.; Tallman, M. S.; Walter, R. B.; Eckardt, J. R.; Collins, R. |
| Abstract Title: | Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML) |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Start Page: | 1071 |
| Language: | English |
| ACCESSION: | WOS:000394446803006 |
| DOI: | 10.1182/blood.V128.22.1071.1071 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 616 -- Source: Wos |
